PortfoliosLab logoPortfoliosLab logo
ELAN vs. IDXX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ELAN vs. IDXX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Elanco Animal Health Incorporated (ELAN) and IDEXX Laboratories, Inc. (IDXX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ELAN vs. IDXX - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
ELAN
Elanco Animal Health Incorporated
2.17%86.87%-18.72%21.93%-56.94%-7.47%4.14%-6.60%-12.42%
IDXX
IDEXX Laboratories, Inc.
-16.54%63.63%-25.51%36.06%-38.04%31.73%91.43%40.38%-23.14%

Fundamentals

Market Cap

ELAN:

$11.49B

IDXX:

$45.55B

EPS

ELAN:

-$0.47

IDXX:

$13.12

PS Ratio

ELAN:

2.44

IDXX:

10.60

PB Ratio

ELAN:

1.75

IDXX:

28.38

Total Revenue (TTM)

ELAN:

$4.72B

IDXX:

$4.30B

Gross Profit (TTM)

ELAN:

$2.59B

IDXX:

$2.66B

EBITDA (TTM)

ELAN:

$874.00M

IDXX:

$1.47B

Returns By Period

In the year-to-date period, ELAN achieves a 2.17% return, which is significantly higher than IDXX's -16.54% return.


ELAN

1D
-3.38%
1M
-11.38%
YTD
2.17%
6M
11.15%
1Y
123.38%
3Y*
34.99%
5Y*
-4.29%
10Y*

IDXX

1D
0.49%
1M
-11.31%
YTD
-16.54%
6M
-8.94%
1Y
34.90%
3Y*
4.13%
5Y*
3.03%
10Y*
21.68%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ELAN vs. IDXX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ELAN
ELAN Risk / Return Rank: 9494
Overall Rank
ELAN Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
ELAN Sortino Ratio Rank: 9595
Sortino Ratio Rank
ELAN Omega Ratio Rank: 9393
Omega Ratio Rank
ELAN Calmar Ratio Rank: 9393
Calmar Ratio Rank
ELAN Martin Ratio Rank: 9696
Martin Ratio Rank

IDXX
IDXX Risk / Return Rank: 7070
Overall Rank
IDXX Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
IDXX Sortino Ratio Rank: 7474
Sortino Ratio Rank
IDXX Omega Ratio Rank: 7272
Omega Ratio Rank
IDXX Calmar Ratio Rank: 6767
Calmar Ratio Rank
IDXX Martin Ratio Rank: 6969
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ELAN vs. IDXX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Elanco Animal Health Incorporated (ELAN) and IDEXX Laboratories, Inc. (IDXX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ELANIDXXDifference

Sharpe ratio

Return per unit of total volatility

2.44

0.80

+1.64

Sortino ratio

Return per unit of downside risk

3.55

1.84

+1.71

Omega ratio

Gain probability vs. loss probability

1.45

1.24

+0.22

Calmar ratio

Return relative to maximum drawdown

4.85

1.26

+3.59

Martin ratio

Return relative to average drawdown

18.09

3.45

+14.64

ELAN vs. IDXX - Sharpe Ratio Comparison

The current ELAN Sharpe Ratio is 2.44, which is higher than the IDXX Sharpe Ratio of 0.80. The chart below compares the historical Sharpe Ratios of ELAN and IDXX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ELANIDXXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.44

0.80

+1.64

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.10

0.09

-0.18

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.66

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.13

0.51

-0.64

Correlation

The correlation between ELAN and IDXX is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Dividends

ELAN vs. IDXX - Dividend Comparison

Neither ELAN nor IDXX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ELAN vs. IDXX - Drawdown Comparison

The maximum ELAN drawdown since its inception was -78.00%, roughly equal to the maximum IDXX drawdown of -81.42%. Use the drawdown chart below to compare losses from any high point for ELAN and IDXX.


Loading graphics...

Drawdown Indicators


ELANIDXXDifference

Max Drawdown

Largest peak-to-trough decline

-78.00%

-81.42%

+3.42%

Max Drawdown (1Y)

Largest decline over 1 year

-24.79%

-27.34%

+2.55%

Max Drawdown (5Y)

Largest decline over 5 years

-78.00%

-54.00%

-24.00%

Max Drawdown (10Y)

Largest decline over 10 years

-54.00%

Current Drawdown

Current decline from peak

-37.04%

-26.35%

-10.69%

Average Drawdown

Average peak-to-trough decline

-39.85%

-20.98%

-18.87%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.64%

9.98%

-3.34%

Volatility

ELAN vs. IDXX - Volatility Comparison

Elanco Animal Health Incorporated (ELAN) has a higher volatility of 14.32% compared to IDEXX Laboratories, Inc. (IDXX) at 8.63%. This indicates that ELAN's price experiences larger fluctuations and is considered to be riskier than IDXX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ELANIDXXDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.32%

8.63%

+5.69%

Volatility (6M)

Calculated over the trailing 6-month period

25.77%

23.61%

+2.16%

Volatility (1Y)

Calculated over the trailing 1-year period

50.81%

43.76%

+7.05%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

44.55%

35.10%

+9.45%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

43.81%

32.84%

+10.97%

Financials

ELAN vs. IDXX - Financials Comparison

This section allows you to compare key financial metrics between Elanco Animal Health Incorporated and IDEXX Laboratories, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


800.00M900.00M1.00B1.10B1.20B1.30BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
1.14B
1.09B
(ELAN) Total Revenue
(IDXX) Total Revenue
Values in USD except per share items

ELAN vs. IDXX - Profitability Comparison

The chart below illustrates the profitability comparison between Elanco Animal Health Incorporated and IDEXX Laboratories, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
74.6%
60.4%
Portfolio components
ELAN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Elanco Animal Health Incorporated reported a gross profit of 853.00M and revenue of 1.14B. Therefore, the gross margin over that period was 74.6%.

IDXX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, IDEXX Laboratories, Inc. reported a gross profit of 658.11M and revenue of 1.09B. Therefore, the gross margin over that period was 60.4%.

ELAN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Elanco Animal Health Incorporated reported an operating income of 562.00M and revenue of 1.14B, resulting in an operating margin of 49.1%.

IDXX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, IDEXX Laboratories, Inc. reported an operating income of 315.61M and revenue of 1.09B, resulting in an operating margin of 28.9%.

ELAN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Elanco Animal Health Incorporated reported a net income of -276.00M and revenue of 1.14B, resulting in a net margin of -24.1%.

IDXX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, IDEXX Laboratories, Inc. reported a net income of 248.19M and revenue of 1.09B, resulting in a net margin of 22.8%.